RE
AVTX icon

RBC Europe’s Avalo Therapeutics AVTX Stock Holding History

RBC Europe’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3
Closed -$7K – 625
2022
Q1 		$7K Buy
+3
New +$7.54K ﹤0.01% 551
2021
Q4 		– Sell
-3
Closed -$20.3K – 675
2021
Q3 		$20.3K Hold
3
– – ﹤0.01% 781
2021
Q2 		$30.4K Hold
3
– – ﹤0.01% 710
2021
Q1 		$28.1K Buy
+3
New +$28.3K ﹤0.01% 679

Other funds holding AVTX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RBC Europe's AVTX Position: Q2 2022 in Review

RBC Europe sold out of Avalo Therapeutics (AVTX) in Q2 2022, closing a stake of 3 shares — an estimated $7K sold.

RBC Europe first reported a position in AVTX in Q1 2021 and held it in 4 quarters. The position peaked at $30.4K in Q2 2021. 43 funds tracked by Wall St. Rank hold AVTX as of Q2 2022.

  • RBC Europe reported no remaining Avalo Therapeutics position as of Q2 2022 after selling out during the quarter.
  • RBC Europe sold 3 Avalo Therapeutics shares in Q2 2022, an estimated $7K.
  • RBC Europe first reported a position in Avalo Therapeutics in Q1 2021 and held it in 4 quarters.
  • RBC Europe's Avalo Therapeutics position peaked at $30.4K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.